Login to Your Account

Washington Roundup

Same Record? Adcoms to Hear Avandia Data 3rd Time

By Mari Serebrov
Washington Editor

Monday, June 3, 2013
Some advisory committee members may think they're listening to a broken record when they convene for the third time in seven years Wednesday to once again discuss the cardiovascular (CV) risk of GlaxoSmithKline plc's (GSK) diabetes drug Avandia and its open-label, noninferiority RECORD trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription